Top Line: After years of dosimetric promise and retrospective hype, do protons finally deliver level I evidence in oropharynx cancer?
The Study: A long-awaited multicenter randomized phase 3 trial compared IMPT (n=221) versus IMRT (n=219) for stage III–IV oropharyngeal SCC treated with concurrent systemic therapy across 21 U.S. centers. The primary endpoint was progression-free survival at 3 years with a non-inferiority margin of 9%. At a median follow-up of 3.2 years, this was accomplished with a 3-year PFS of 83% in both arms. Disease control was equivalent across local, regional, and distant failures. As hoped, toxicity favored protons: IMPT appeared to significantly reduce grade ≥3 dysphagia (34% vs 49%), xerostomia (33% vs 45%), severe lymphopenia (76% vs 89%), and gastrostomy-tube dependence at 60 days (27% vs 40%). But alas we have buried the lead: a significant overall survival emerged at 5 years: 91% after IMPT vs 81% after IMRT, though this was a secondary endpoint and mechanisms remain speculative. The latter part does not keep the authors from concluding: “IMPT is a new standard-of-care treatment option for patients with oropharyngeal cancer.”
TBL: IMPT for oropharyngeal cancer delivers comparable control with meaningfully less morbidity that potentially translates to better survival. | Frank, Lancet 2025
The Study: A long-awaited multicenter randomized phase 3 trial compared IMPT (n=221) versus IMRT (n=219) for stage III–IV oropharyngeal SCC treated with concurrent systemic therapy across 21 U.S. centers. The primary endpoint was progression-free survival at 3 years with a non-inferiority margin of 9%. At a median follow-up of 3.2 years, this was accomplished with a 3-year PFS of 83% in both arms. Disease control was equivalent across local, regional, and distant failures. As hoped, toxicity favored protons: IMPT appeared to significantly reduce grade ≥3 dysphagia (34% vs 49%), xerostomia (33% vs 45%), severe lymphopenia (76% vs 89%), and gastrostomy-tube dependence at 60 days (27% vs 40%). But alas we have buried the lead: a significant overall survival emerged at 5 years: 91% after IMPT vs 81% after IMRT, though this was a secondary endpoint and mechanisms remain speculative. The latter part does not keep the authors from concluding: “IMPT is a new standard-of-care treatment option for patients with oropharyngeal cancer.”
TBL: IMPT for oropharyngeal cancer delivers comparable control with meaningfully less morbidity that potentially translates to better survival. | Frank, Lancet 2025